Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 8/20 | 0.59 |
| ▸ | DRD4 | P21917 | 8/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.55 |
| ▸ | CCR2 | P41597 | 1/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153437 | 0.93 | ROCK2 (0.60) | GAADRD2DRD4LTA4HROCK2 | |
| SCHEMBL6153555 | 0.93 | LTA4H (0.66) | GAADRD2DRD4LTA4HROCK2 | |
| Hydrochloric Acid SCHEMBL6157025 | 0.91 | LTA4H (0.65) | GAADRD2DRD4LTA4HROCK2 | |
| SCHEMBL6154433 | 0.88 | LTA4H (0.61) | GAADRD2DRD4LTA4HROCK2 | |
| SCHEMBL331018 | 0.84 | BCHE (0.68) | GAADRD2DRD4ROCK2CCR2 | |
| SCHEMBL331017 | 0.84 | BCHE (0.68) | GAADRD2DRD4ROCK2CCR2 | |
| SCHEMBL6399559 | 0.84 | OPRD1 (0.58) | DRD2DRD4LTA4HROCK2CCR2 | |
| SCHEMBL4229314 | 0.82 | LTA4H (0.80) | DRD2DRD4LTA4HROCK2CCR2 | |
| SCHEMBL8608140 | 0.81 | CA12 (0.67) | GAADRD2DRD4LTA4HKCNH2 | |
| SCHEMBL4222813 | 0.80 | HTR2A (0.62) | DRD2DRD4ROCK2CCR2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | GAA 2875/4885DRD2 3058/4885DRD4 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.